Efficacy and safety of switching to once-daily oral doravirine plus raltegravir in virologically suppressed people with HIV-1: a randomized, open-label, multicentre phase 2 study (DORAL). (academic.oup.com)

Authors: Palich R … Katlama C Journal: Journal of Antimicrobial Chemotherapy Published: 2026-10-06 DOI: https://doi.org/10.1093/jac/dkag336